

In the Specification:

At page 17, please amend the following paragraph:

--In certain preferred embodiments of the invention, the antibodies are scAbs, in particular scAbs that are obtained from E. coli clones designated as XL1-Blue G3H5, G3B12, G3G2 and/or G3H3. The clones have been deposited at NCIMB Ltd., 23 St Machar Drive, Aberdeen, AB24 3RY, Scotland ~~UK~~ on 18 March 2003 under the terms of the Budapest Treaty under the following accession numbers: G3H5 deposited as NCIMB-41167, G3B12 deposited as NCIMB-41168, G3G2 deposited as NCIMB-41169 and G3H3 deposited as NCIMB-41170. The strains may be cultivated in an appropriate growth media such as LB media supplemented with 100 µg/ml ampicillin, optionally supplemented with 12.5 µg/ml tetracycline, and/or 1% glucose, under standard conditions of 37 °C in air.--